Table 3.
An overview of clinical trials for personalized neoantigen-based DC vaccines
| Vaccine type | Clinical trial number | Phase | Recruitment status | First posted | Locations | Cancer types | Vaccine name | Administration route of vaccine |
|---|---|---|---|---|---|---|---|---|
| Neoantigen-sensitized DC | NCT05235607 | I | Not yet recruiting | 2022.02.11 | China Sichuan University |
Carcinoma Melanoma Bladder cancer CRC |
- | s.c. |
| Peptide-pulsed DC | NCT05749627 | Not Applicable | Recruiting | 2023.03.01 | China The First Affiliated Hospital of Nanchang University Shenzhen Dengding Biopharma Co. Ltd. |
Advanced malignant solid tumors | - | s.c. |
| Peptide-pulsed DC | NCT05714306 | I/II | Not yet recruiting | 2023.02.06 | Suisse Centre Hospitalier Universitaire Vaudois |
High-grade serous ovarian carcinoma | PEP-DC | Intra-nodally |
| HOCl-oxidized autologous tumor lysate and personal neoantigen-sensitized DC | NCT05317325 | I | Not yet recruiting | 2022.04.07 | China Sichuan University |
Esophageal squamous cell carcinoma | - | s.c. |
| Peptide-pulsed DC | NCT05195619 | I | Recruiting | 2022.01.19 | Switzerland Centre Hospitalier Universitaire Vaudois |
NSCLC | - | s.c. |
| Neoantigen-sensitized DC | NCT05023928 | I | Not recruiting | 2021.08.27 | China Sichuan University |
Esophageal cancer | - | s.c. |
| Neoantigen-sensitized DC | NCT05020119 | I | Recruiting | 2021.08.25 | China Chang Gung Memorial Hospital |
Advanced solid tumor | - | i.v.gtt |
| Neoantigen-pulsed DC | NCT04912765 | II | Recruiting | 2021.06.03 | Singapore National Cancer Centre, Bristol-Myers Squibb |
Hepatocellular carcinoma CRCLiver metastases |
- | i.d. |
| Peptide-pulsed DC | NCT04627246 | I | Recruiting | 2020.11.13 | Switzerland Centre Hospitalier Universitaire Vaudois |
Pancreatic adenocarcinoma | PEP-DC | s.c. |
| Peptide-pulsed DC | NCT04147078 | I | Unknown | 2019.10.31 | China Sichuan University |
Gastric cancer Hepatocellular carcinoma NSCLC CRC |
- | s.c. |
| Peptide-pulsed DC | NCT04105582 | I | Completed | 2019.09.26 | Colombia Universidad National de Colombia Fundación Salud De Los Andes |
Breast cancer Triple-negative breast cancer |
- | - |
| mRNA-pulsed DC | NCT04082182 | I | Unknown | 2019.09.09 | Belgium University Hospital University Ghent Kom Op Tegen Kanker |
NSCLC | MIDRIX4-LUNG | i.v.gtt |
| mRNA-pulsed DC | NCT04078269 | I | Active, not recruiting | 2019.09.06 | Belgium University Hospital, Ghent University Ghent Kom Op Tegen Kanker |
NSCLC | MIDRIXNEO-LUNG | i.v.gtt |
| Neoantigen-pulsed DC | NCT03871205 | I | Unknown | 2019.03.12 | China Shenzhen People’s Hospital |
Carcinoma, NSCLC, SCLC |
- | s.c. |
| Peptide-pulsed DC | NCT03730948 | I | Terminated (lack of enrollment) | 2018.11.05 | United States University of Pennsylvania |
CRC | mDC3 | - |
| Neoantigen-pulsed DC | NCT03674073 | I | Unknown | 2018.09.17 | China Chinese PLA General Hospital, Likang Life Sciences Holdings Limited |
Hepatocellular carcinoma |
- | - |
| Peptide-pulsed DC | NCT03300843 | II | Terminated (slow accrual) | 2017.10.04 | United States National Cancer Institute (NCI) |
Melanoma Gastrointestinal cancer Breast cancer Ovarian cancer Pancreatic cancer |
- | i.v.gtt & s.c. |
| Neoantigen-pulsed DC | NCT03205930 | I/II | Not recruiting | 2017.07.02 | China The First People’s Hospital of Lianyungang Hengrui Yuanzheng Bio-Technology Co., Ltd. |
NSCLC (stage IV) | Neo-MASCT | s.c. |
| Peptide-pulsed DC | NCT03185429 | I | Unknown | 2017.06.14 | China BGI, Fujian Cancer Hospital |
Gastrointestinal solid tumor | Neo-MoDC | s.c. |
| Peptide-pulsed DC | NCT03092453 | I | Active, not recruiting | 2017.03.28 | United States University of Pennsylvania |
Melanoma | - | - |
| Peptide-pulsed DC | NCT02956551 | I | Unknown | 2016.11.06 | China Sichuan University |
NSCLC | Neo-DCVac | s.c. |
CRC, colorectal cancer; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; mRNA, messenger ribonucleic acid; DC, dendritic cell; i.d., intradermal; i.v.gtt, intravenous infusions; s.c., subcutaneous.